Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2008;336:233-234 (2 February), doi:10.1136/bmj.39472.508056.3A
| The first 150 words of the full text of this article appear below. |
The study by Asghar et al and the accompanying editorial by Bhutta remind all of us that much more can and must be done to control pneumonia and pneumococcal disease world wide.1 2 The All Party Parliamentary Group on Pneumococcal Disease Prevention in the Developing World was formed last month to tackle the devastating impact of pneumonia on child survival. The group is committed to raising awareness of pneumococcal disease and pneumonia, vaccination strategies, and sustainable financing mechanisms among MPs and peers nationally, across Europe, and around the world.
As Bhutta notes, given increasing resistance to antibiotics in the long term, the most cost effective means of reducing child mortality from pneumonia is to scale up effective preventive strategies, most notably vaccination. Pneumococcal conjugate vaccines are safe and highly effective in preventing pneumococcal pneumonia and meningitis.
GAVIs PneumoADIP is working to accelerate the introduction of these vaccines so that they can
Des Turner, chair, Richard Taylor, executive officer
1 All-Party Parliamentary Group on Pneumococcal Disease Prevention in the Developing World, House of Commons, London SW1A 0AA
turnerd@parliament.uk
Read all Rapid Responses
Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.